These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 11166451)
1. Bone marrow stem cell protection from chemotherapy by low--molecular-weight compounds. Guest I; Uetrecht J Exp Hematol; 2001 Feb; 29(2):123-37. PubMed ID: 11166451 [TBL] [Abstract][Full Text] [Related]
2. Clinical status of the new cytoprotective agent, amifostine. Kalaycioglu M; Bukowski R Oncology (Williston Park); 1994 Jul; 8(7):15-6, 19-20, 23. PubMed ID: 7522504 [TBL] [Abstract][Full Text] [Related]
10. Effect of the immunomodulator AS101 on chemotherapy-induced multilineage myelosuppression, thrombocytopenia, and anemia in mice. Kalechman Y; Rushkin G; Nerubay J; Albeck M; Sredni B Exp Hematol; 1995 Dec; 23(13):1358-66. PubMed ID: 7498364 [TBL] [Abstract][Full Text] [Related]
11. Epigenetic and microenvironmental alterations in bone marrow associated with ROS in experimental aplastic anemia. Chatterjee R; Law S Eur J Cell Biol; 2018 Jan; 97(1):32-43. PubMed ID: 29173808 [TBL] [Abstract][Full Text] [Related]
12. The protective role of ammonium trichloro(dioxoethylene-O,O')tellurate in combination with several cytotoxic drugs acting by different mechanisms of action. Kalechman Y; Shani A; Sotnik-Barkai I; Albeck M; Sredni B Cancer Res; 1993 Dec; 53(24):5962-9. PubMed ID: 8261410 [TBL] [Abstract][Full Text] [Related]
13. The use of haemoregulatory peptides (pEEDCK monomer and dimer) for reduction of cytostatic drug induced haemopoietic damage. Paukovits WR; Moser MH; Binder KA; Paukovits JB Cancer Treat Rev; 1990 Sep; 17(2-3):347-54. PubMed ID: 2272050 [TBL] [Abstract][Full Text] [Related]
14. Allopurinol and cytotoxic drugs. Interaction in relation to bone marrow depression. Boston Collaborative Drug Surveillance Program. JAMA; 1974 Mar; 227(9):1036-40. PubMed ID: 4405931 [No Abstract] [Full Text] [Related]
15. Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants. Douay L; Hu C; Giarratana MC; Gorin NC Semin Oncol; 1994 Oct; 21(5 Suppl 11):16-20. PubMed ID: 7973773 [TBL] [Abstract][Full Text] [Related]
16. Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide. Sredni B; Albeck M; Tichler T; Shani A; Shapira J; Bruderman I; Catane R; Kaufman B; Kalechman Y J Clin Oncol; 1995 Sep; 13(9):2342-53. PubMed ID: 7666093 [TBL] [Abstract][Full Text] [Related]
17. The membrane-bound isoform of stem cell factor synergizes with soluble flt3 ligand in supporting early hematopoietic cells in long-term cultures of normal and aplastic anemia bone marrow. Slanicka Krieger M; Nissen C; Manz CY; Toksoz D; Lyman SD; Wodnar-Filipowicz A Exp Hematol; 1998 May; 26(5):365-73. PubMed ID: 9590652 [TBL] [Abstract][Full Text] [Related]
19. Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects. Douay L; Hu C; Giarratana MC; Gorin NC Eur J Cancer; 1995; 31A Suppl 1():S14-6. PubMed ID: 7577094 [TBL] [Abstract][Full Text] [Related]
20. Genomic insult oriented mitochondrial instability and proliferative hindrance in the bone marrow of aplastic mice including stem/progenitor population. Chatterjee R; Law S Pathol Res Pract; 2019 Apr; 215(4):784-793. PubMed ID: 30683472 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]